|
|
Article: Pharmacopeia Rises On Deal With Cephalon: $15M Up Front.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Shares of Pharmacopeia Drug Discovery Inc. jumped 26.3 percent after the company signed a drug discovery deal with Cephalon Inc. that includes a $15 million up-front fee and the potential for double-digit royalties.
The collaboration will focus on moving molecules to proof of concept, with Cephalon responsible for identifying the compounds and Pharmacopeia handling "the bulk of the work in medicinal chemistry and biology," said Les Browne, president and CEO of Princeton, N.J.-based Pharmacopeia.
The $15 million up-front program access fee is a "nice way of improving our cash position, something that's always challenging for a ...
Related newspaper, magazine, and journal articles:
|